Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953612 · ClinicalTrials.gov registry record · Early Phase 1
The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 58
- Enrollment target
NCT03953612 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 58 participants.
The verdict
NCT03953612, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with cocaine use disorder (CUD).
Interventions
- DRUG Placebos
- DRUG Pregnenolone (PREG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2023-05-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953612
The ClinicalTrials.gov registry entry for NCT03953612 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03953612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953612 about?
NCT03953612 is a clinical study titled "The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders". To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with cocaine use disorder (CUD).
What is the current status of trial NCT03953612?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2019-03-12. Estimated completion is 2023-05-08.
What interventions are being tested in trial NCT03953612?
The interventions under investigation include: Placebos (DRUG), Pregnenolone (PREG) (DRUG).
Who is sponsoring clinical trial NCT03953612?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.